KAPSPARGO SPRINKLE (metoprolol succinate)
KAPSPARGO SPRINKLE is indicated for the treatment of Hypertension; Angina Pectoris; Heart Failure.
How KAPSPARGO SPRINKLE Works
Metoprolol succinate is a cardioselective beta-1 adrenergic receptor blocker. At therapeutic doses, it preferentially inhibits beta-1 receptors located chiefly in cardiac muscle, resulting in a decrease in heart rate, cardiac output, and AV nodal conduction. It lacks intrinsic sympathomimetic activity. Its antihypertensive effects are attributed to several mechanisms, including competitive antagonism of catecholamines at peripheral adrenergic neuron sites (leading to decreased cardiac output), reduction of sympathetic outflow from the central nervous system, and suppression of renin activity. At higher plasma concentrations, metoprolol’s selectivity diminishes, and it may inhibit beta-2 adrenoreceptors in the bronchial and vascular musculature.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2018-01-26
- Patent Cliff
- 2035
- Routes
- ORAL
- Dosage Forms
- CAPSULE, EXTENDED RELEASE
KAPSPARGO SPRINKLE Approval History
What KAPSPARGO SPRINKLE Treats
3 indicationsKAPSPARGO SPRINKLE is approved for 3 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypertension
- Angina Pectoris
- Heart Failure
KAPSPARGO SPRINKLE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in KAPSPARGO SPRINKLE's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications KAPSPARGO SPRINKLE treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to KAPSPARGO SPRINKLE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
18 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07490067 | HUM00266021 1R01HL178410-01 | Ph 4 | recruiting | Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score |
| NCT04434664 BLOCK HFpEF results posted | 833517 | Ph 4 | completed | BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF |
| NCT05931276 BRAVO | 2026 | Ph 3 | recruiting | CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes |
| NCT06964464 CARVTOP-ICD | STUDY00010093 PLACER-2023C3-33489 | Ph 4 | recruiting | Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator |
| NCT03778554 DANBLOCK | 2018-002699-42 2018-002699-42 | Ph 4 | active not recruiting | Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction |
| NCT05711810 | SARSCoVVaxPoison | Ph 4 | completed | Medicine-induced Cardiac Hemodialysis on COVID-19 |
| NCT01970501 GENETIC-AF results posted | BUC-CLIN-303 | Ph 2 | completed | Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure |
| NCT05066633 MeDMD | NBK 154/1/2020 2020-004901-29 | Ph 3 | recruiting | The Efficacy and Safety of Metoprolol as add-on Treatment to Standard of Care in Preventing Cardiomyopathy in Patients With DMD |
| NCT03532802 TEMPO | 1-10-72-441-17 | Ph 2 | completed | The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy. |
| NCT02587351 results posted | 1512M81981 | Ph 3 | terminated | Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease |
| NCT01502787 results posted | STU 062011-072 | Ph 4 | completed | Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients |
| NCT01501929 results posted | Bystolic MD52 | Ph 4 | completed | Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients |
| NCT01041287 results posted | IRB00013262 BYD-MD-20 | Ph 4 | completed | Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells |
| NCT01499134 ENCOMPASS results posted | 11C.18 | Ph 3 | completed | Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure |
| NCT01676285 CARE Cirrhosis | 0010/11 | Ph 3 | completed | Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis |
| NCT01605370 Inapprop results posted | 11-007035 | Ph 4 | terminated | Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients? |
| NCT01694797 | 642/09 | Ph 1 | completed | Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition |
| NCT01673997 | P-643/09 | Ph 1 | completed | Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KAPSPARGO SPRINKLE FDA Label Details
Indications & Usage
FDA Label (PDF)KAPSPARGO SPRINKLE is indicated for the treatment of Hypertension; Angina Pectoris; Heart Failure.
Pro Intelligence Preview
Deep insights for KAPSPARGO SPRINKLE
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2035
- • 32 active patents
Trial Analysis
- • 18 total trials
- • Stage: Mature
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment